The Search for a Drug to End Alzheimer’s
https://www.embs.org/pulse/wp-content/uploads/sites/13/2021/04/Campbell-iStock-912219896.jpg
2139
1402
IEEE Pulse
//www.embs.org/pulse/wp-content/uploads/sites/13/2024/03/ieee-pulse-logo-dsktp2x.png
On November 6, 2020, researchers who have been laboring to find a drug that will treat Alzheimer’s disease (AD) dialed in to a public meeting of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee. The committee would review drug trials of Biogen’s aducanumab, and conclude with a vote on the drug’s safety and efficacy in treating AD. The independent advisors’ decision wouldn’t be the official one for aducanumab, but their vote usually mirrors the final FDA decision.
read more